The 3 way combo produced 4 treatment related deaths, vibostolimab/pembro 1 treatment related death and mono docetaxel 1 treatment related death. DCVax-L looks pretty good compared to these toxic therapies. I wonder what patients will want when they find out about L being a platform treatment and only mild treatment related events compared to being offered toxic treatments like these in clinical studies?; ). Best wishes.
Market Data 
Markets 
